<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9330">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05700357</url>
  </required_header>
  <id_info>
    <org_study_id>E.Kurul-E1-22-3143</org_study_id>
    <nct_id>NCT05700357</nct_id>
  </id_info>
  <brief_title>Different Local Anesthetic Volumes for TPVB in Post-thoracotomy Analgesia</brief_title>
  <official_title>Comparison of Different Local Anesthetic Volumes of Thoracic Paravertebral Block Application in Post-thoracotomy Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara City Hospital Bilkent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara City Hospital Bilkent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thoracotomy is one of the most painful operations known. Therefore, it causes severe acute&#xD;
      pain. If pain is not controlled, it increases the frequency of postoperative pulmonary&#xD;
      complications and postoperative morbidity. It can even cause chronic pain in the future.&#xD;
      Thoracic epidural analgesia (TEA) is the gold standard method in the treatment of pain after&#xD;
      thoracotomy. Thoracic paravertebral block (TPVB) is known as the most effective method after&#xD;
      TEA. The fact that TPVB has fewer side effects than TEA increases the use of TPVB. There is&#xD;
      no consensus on the dose of analgesia in studies. In the literature, volumes between 20 ml&#xD;
      and 30 ml are frequently used for TPVB in recent years. This study, it was aimed to compare&#xD;
      the efficacy of 20 ml, 25 ml, and 30 ml volumes of TPVB with local anesthetic at the same&#xD;
      concentration (0.25% bupivacaine) on postoperative analgesia in patients undergoing&#xD;
      thoracotomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2022</start_date>
  <completion_date type="Anticipated">December 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>1st hour after surgery</time_frame>
    <description>Pain will be assessed at the first-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>2nd-hour after surgery</time_frame>
    <description>Pain will be assessed at the 2nd-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>4th-hour after surgery</time_frame>
    <description>Pain will be assessed at the 4th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>12th-hour after surgery.</time_frame>
    <description>Pain will be assessed at the 12th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>24th-hour after surgery.</time_frame>
    <description>Pain will be assessed at the 24th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>48th-hour after surgery.</time_frame>
    <description>Pain will be assessed at the 48th-hour rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine Consumption</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Morphine consumption for 24 hours will be recorded</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Thoracic Paravertebral Block</condition>
  <condition>Thoracotomy</condition>
  <condition>Postoperative Analgesia</condition>
  <condition>Acute Pain</condition>
  <condition>Local Anesthetic</condition>
  <arm_group>
    <arm_group_label>Thoracic Paravertebral Block 20 ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 20 ml of 0.25% bupivacaine will be injected into this area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic Paravertebral Block 25 ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 25 ml of 0.25% bupivacaine will be injected into this area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic Paravertebral Block 30 ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients who are planned to have a thoracic paravertebral block, the needle will be advanced to the paravertebral area with ultrasound-guided in-plane technique. 30 ml of 0.25% bupivacaine will be injected into this area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TPVB with 20 ml</intervention_name>
    <description>The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.</description>
    <arm_group_label>Thoracic Paravertebral Block 20 ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TPVB with 25 ml</intervention_name>
    <description>The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.</description>
    <arm_group_label>Thoracic Paravertebral Block 25 ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TPVB with 30 ml</intervention_name>
    <description>The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.</description>
    <arm_group_label>Thoracic Paravertebral Block 30 ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 80 years old&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status I-II-III&#xD;
&#xD;
          -  BMI 18 to 40 kg/m2&#xD;
&#xD;
          -  Elective thoracotomy surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusing the procedure&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  History of chronic opioid or analgesic used&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emine N ZENGİN</last_name>
    <phone>+905063370548</phone>
    <email>nilbavullu@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ankara City Hospital</name>
      <address>
        <city>Çankaya</city>
        <state>Ankara</state>
        <zip>06290</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emine N Zengin, MD</last_name>
      <phone>+905063370548</phone>
      <email>nilbavullu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 7, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara City Hospital Bilkent</investigator_affiliation>
    <investigator_full_name>Nilgün Zengin</investigator_full_name>
    <investigator_title>Principal İnvestigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

